Amlodipine/celecoxib, sold under the brand name Consensi, is a fixed-dose combination medication used to treat both hypertension and osteoarthritis at the same time in adults. It contains amlodipine besylate and celecoxib. It is taken by mouth.The most common side effects include edema, abdominal pain, diarrhea, dyspepsia, flatulence, peripheral edema, accidental injury, dizziness, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection, and rash.It was approved for medical use in the United States in May 2018. Medical uses
Amlodipine/celecoxib is indicated for use in adults for whom treatment with amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. History
Amlodipine/celecoxib was approved for use in the United States in May 2018. References
External links
"Amlodipine mixture with celecoxib". Drug Information Portal. U.S. National Library of Medicine.
Medications
With benign prostatic enlargement causes of LUTS, people may be offered a variety of medications (as a single drug or combining them) when there are persistent moderate symptoms:
Alpha blockers
5-alpha reductase inhibitors
Phosphodiesterase inhibitors
Muscarinic receptor antagonists
Plants extracts (phytotherapy)
Beta-3 agonistIf medical treatment fails, or is not an option; a number of surgical techniques to destroy part or all of the prostate have been developed. Surgical treatment
Surgical treatment of LUTS can include:

Ablation procedures - used in treating both bladder tumours and bladder outlet obstruction, such as prostate conditions. Bladder-neck incision (BNI)
Removal of the prostate - open, robotic, and endoscopic techniques are used. Stenting of the prostate and urethra. Transurethral resection of the prostate (TURP)
Transurethral microwave thermotherapy
Urethral dilatation, a common treatment for strictures. Epidemiology
Prevalence increases with age. The prevalence of nocturia in older men is about 78%. Older men have a higher incidence of LUTS than older women. Around one third of men will develop urinary tract (outflow) symptoms, of which the principal underlying cause is benign prostatic hyperplasia. Once symptoms arise, their progress is variable and unpredictable with about one third of patients improving, one third remaining stable and one third deteriorating. References
Further reading
External links

LUTS in men - Patient.info
LUTS in women - Patient.info